Detalhe da pesquisa
1.
Heterozygosity for bisphosphoglycerate mutase deficiency expressing clinically as congenital erythrocytosis: A case series and literature review.
Br J Haematol
; 200(2): 249-255, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36177683
2.
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia.
Am J Hematol
; 98(12): 1877-1887, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671681
3.
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study.
Am J Hematol
; 97(7): E226-E229, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384026
4.
A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.
EJHaem
; 5(1): 21-32, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38406513
5.
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme.
Blood Rev
; 61: 101103, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37353463
6.
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.
Blood Adv
; 7(24): 7539-7550, 2023 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37934880
7.
Corrigendum to "Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme" [Blood Rev. 2023 Sep:61:101103].
Blood Rev
; 64: 101160, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38044254